Skip to content

Author

K. Steiger

We have 10 of 651 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

KDM6 Histone Demethylases Tune Pancreatic Cancer Plasticity.

Aberrant epigenetic regulation is a central driver of tumorigenesis, and the reversibility of epigenetic modifications underscores their potential as therapeutic targets. Epigenetic factors often function in a highly context-dependent manner, necessitating rigorous study of their dynamic and complex roles. Here, we unc...

Laura Leonhardt, Jia-Zhuan Mei, Audrey M. Hendley et al. · 0 citations
Open access Sep 2026

Spatial transcriptomics reveal impaired metabolic liver zonation in acute-on-chronic liver failure.

BACKGROUND AND AIMS Extrahepatic organ failures are key determinants of acute-on-chronic liver failure (ACLF). While the role of systemic inflammation and mitochondrial dysfunction in the pathogenesis of ACLF is well known, the contribution of the liver itself is less understood. We therefore performed transcriptome an...

Mona-May Langer, H. Stadler, M. Mannewitz et al. · 0 citations
Oct 2026

Preclinical Evaluation on the Radiohybrid Tandem [18F]La- and [225Ac]Ac-rhPSMA-10.1 for Targeted α-Therapy of Prostate Cancer.

Prostate-specific membrane antigen (PSMA)-targeted α-therapy holds promise for the treatment of prostate cancer but has increased side effects compared with therapy using β-emitting PSMA ligands. This emphasizes the need for precise imaging of the biodistribution of 225Ac-labeled ligands for patient selection and dosim...

Bai-Qing Sun, Daniel Werner, Jun-Cheng Ni et al. · 0 citations
Open access Sep 2026

Multimodal Imaging of Hypoxia, Metabolism and pH in Feline Sarcoma Using Hyperpolarized 13C MRI and PET

ABSTRACT Direct in vivo characterization of the interplay between tumor hypoxia, acidosis, and metabolic reprogramming remains a major translational challenge. Here, we establish a clinically deployable simultaneous PET/MRI workflow on a clinical 3 T system that combines hyperpolarized 13C MRI of [1‐13C]pyruvate to map...

Martin Grashei, Tanja Groll, S. Kahl et al. · 0 citations
Sep 2026

Abstract A027: Loss of the Y chromosome drives basal identity and metastatic potential via epigenetic reprogramming in pancreatic cancer

It is demonstrated for the first time that LOY is significantly enriched in advanced-stage disease and the aggressive basal molecular subtype, establishing LOY as a causal genetic driver of PDAC progression, acting through epigenetic remodeling to promote EMT, basal subtype identity, metastasis, and therapy resistance.

M. Dorsch, Felix E. G. Beaudry, A. Baginska et al. · 0 citations
Open access Sep 2026

Anti-CD40L prevents meningeal B cell aggregates and mitigates progressive autoimmune encephalomyelitis.

Anti-CD40L treatment may be an effective intervention to mitigate progressive immunopathology associated with meningeal TLS, and modulates and likely silences other CD40-dependent antigen-presenting cells in the CNS, including myeloid cells and astrocyte subsets.

Sofia Tyystjärvi, Diego Ruiz Navarro, Leni-Mihaela Kulisch et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.